Regular Article
Mechanism of Aminobisphosphonate Action: Characterization of Alendronate Inhibition of the Isoprenoid Pathway

https://doi.org/10.1006/bbrc.1999.1849Get rights and content

Abstract

Alendronate (ALN), an aminobisphosphonate compound used for the treatment of osteoporosis and other disorders of bone resorption, has been suggested to act by inhibition of the formation of GGPP. In the present study we used an S10 homogenate fraction of rat liver to show that ALN causes a dose-dependent inhibition of [3H]MVA incorporation into sterols and a concomitant increase in incorporation of radiolabel into IPP and DMAPP. We further show that ALN is a potent inhibitor of cytosolic trans-prenyltransferase (FPP synthase). The inhibition is competitive with respect to allylic pyrophosphate substrates, but not IPP, suggesting that ALN acts as an allylic pyrophosphate analog and binds to the free enzyme. The Ki is in the 0.5 μM range.

References (23)

  • M.H. Gelb et al.

    Curr. Opin. Chem. Biol.

    (1998)
  • J. Sun et al.

    J. Biol. Chem.

    (1999)
  • E. van Beek et al.

    Biochem. Biophys. Res. Commun.

    (1999)
  • S.J. Fliesler et al.

    Int. J. Biochem. Cell Biol.

    (1997)
  • N.L.R. Bucher et al.

    J. Biol. Chem.

    (1956)
  • R.K. Keller et al.

    J. Chromatog.

    (1993)
  • R.K. Keller

    Biochim. Biophys. Acta

    (1996)
  • H.C. Rilling

    Methods Enzymol.

    (1985)
  • T.L. McKenzie et al.

    J. Biol. Chem.

    (1992)
  • A. Baxter et al.

    J. Biol. Chem.

    (1992)
  • E. Van Beek et al.

    Biochem. Biophys. Res. Commun.

    (1999)
  • Cited by (87)

    • Cellular and molecular actions of bisphosphonates

      2021, Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside
    • Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton

      2020, Bone
      Citation Excerpt :

      Frustratingly, these studies were repeatedly turned down for publication by several leading journals (dismissed in a single sentence by one manuscript reviewer as being “too far-fetched”) and took almost 3 years to be published, finally appearing in print in 1998 [9,46] and reprinted in 2005 as an “Anniversary Classic” in J Bone Miner Res; one of the most highly cited articles in the journal's history. Soon after these revelatory findings, the enzyme target in the mevalonate pathway was identified as farnesyl diphosphate synthase (FPP synthase, also known as FDPS), a crucial enzyme at the branch point of isoprenoid lipid and cholesterol biosynthesis (Fig. 4) [6,49–52]. Since then it has become clear that N-BPs can also inhibit, albeit less potently, other enzymes in the mevalonate pathway including isopentenyl diphosphate (IPP) isomerase and geranylgeranyl diphosphate (GGPP) synthase [53,54], as well as squalene synthase [43,55].

    • Cellular and molecular actions of bisphosphonates

      2015, Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition
    View all citing articles on Scopus
    1

    To whom correspondence should be addressed at Saint Louis University Eye Institute, 1755 South Grand Boulevard, St. Louis, MO 63104-1540. Fax: (314) 771-0596. E-mail: [email protected].

    View full text